CERUS Business Summary

Cerus Corporation (CERS) is a biomedical products company that generates revenue primarily through the sale of its INTERCEPT Blood System, a proprietary pathogen inactivation technology designed to safeguard the global blood supply. The company operates within a single business segment, Blood Safety, where it monetizes the sale of disposable kits and illuminator devices used to treat platelets and plasma, as well as its INTERCEPT Fibrinogen Complex (IFC), which received a significant commercial boost in 2025. Cerus is currently expanding its footprint into the red blood cell (RBC) market through its INT200 program and a major contract with BARDA. Its primary direct competitors include Terumo BCT, Haemonetics, and Macopharma; Cerus distinguishes itself as a specialized leader in pathogen reduction, maintaining a dominant market share in the inactivation of transfusion-transmitted infections compared to broader medical supply peers. The company was co-founded by Dr. Laurence M. Corash, who currently serves as Chief Scientific Officer and is a renowned expert in laboratory medicine from UCSF. Leadership is led by William "Obi" M. Greenman, who has served as President and CEO since 2011 and assumed the role of Chairman of the Board in June 2025. The executive suite includes Chief Operating Officer Vivek K. Jayaraman, Chief Financial Officer Kevin D. Green, and Chief Medical Officer Dr. Richard J. Benjamin, formerly of the American Red Cross. Cerus maintains a high-profile institutional investor base, with significant holdings from ARK Investment Management, BlackRock, and Vanguard. The board is further strengthened by Lead Independent Director Dr. Frank Witney, an Operating Partner at Ampersand Capital Partners, and directors with deep industry ties to organizations like Stanford University and Intuitive Surgical.